Back to search

Article

Apatinib with first-generation EGFR-TKIs as second-line treatment for patients with advanced non-small cell lung cancer with acquired resistance: a retrospective case series analysis

2023-02-01

Abstract excerpt

<h4>Background: </h4> Resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) develops in most patients with non-small cell lung cancer (NSCLC) and negates the effects of the drug. Herein we try to explore a feasible method for patients with acquired resistance to first-generation EGFR-TKIs. <h4>Methods: </h4>: This study primary assessed the efficacy of first-generation EGFR-TKIs...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
fb824954-9397-5507-b6fe-91b134c59003
DOI
10.21203/rs.3.rs-2531747/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Apatinib with first-generation EGFR-TKIs as second-line treatment for patients with advanced non-small cell lung cancer with acquired resistance: a retrospective case series analysisDOI 10.21203/rs.3.rs-2531747/v1
Apatinib added when NSCLC patients get slow progression with EGFR-TKI: A prospective, single-arm study.Semantic proximity
REPORT- Clinical outcomes of using second - versus first-Generation EGFR-tkis for the First-Line treatment of advanced NSCLC patients with EGFR mutations: A meta-analysis.Semantic proximity
Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance.Semantic proximity
First-line Aumolertinib (EGFR tyrosine kinase inhibitor) plus apatinib (VEGFR inhibitor) versus aumolertinib in EGFR-mutant non-small cell lung cancer patients: a randomized, multicenter, phase II trial.Semantic proximity
The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients.Semantic proximity
[Targeted Therapy and Mechanism of Drug Resistance in Non-small Cell Lung Cancer with Epidermal Growth Factor Receptor Gene Mutation].Semantic proximity
[Precision first-line therapy for advanced non-small-cell lung cancer patients harboring EGFR mutation].Semantic proximity
First-Line Afatinib plus Cetuximab for EGFR-Mutant Non-Small Cell Lung Cancer: Results from the Randomized Phase II IFCT-1503 ACE-Lung Study.Semantic proximity
[Precision treatment after resistance to first-generation EGFR-TKI in patients with non-small cell lung cancer].Semantic proximity
Afatinib plus bevacizumab combination after acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: Multicenter, single-arm, phase 2 trial (ABC Study).Semantic proximity
[Treatment strategy for activating EGFR-mutated non-small cell lung cancer after failure of first-generation EGFR-TKIs].Semantic proximity
Clinical characteristics of non-small cell lung cancer patients who experienced acquired resistance during gefitinib treatment.Semantic proximity
Select a neighboring publication to make it the new centre.